The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)
Johannes Brettschneider, Anne Czerwoniak, Makbule Senel et al. · 2010
Read The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS) by Johannes Brettschneider, Anne Czerwoniak, Makbule Senel et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0011986.txt.
Description
Johannes Brettschneider and co-workers tested in 2010 a spinal fluid signal that might forecast the course of a first multiple sclerosis-like episode. The episode type is called clinically isolated syndrome, and only some patients go on to full multiple sclerosis. B lymphocytes are now thought to matter in the disease, so B cell signals in spinal fluid are promising candidates.
The team evaluated CXCL13, a chemical that attracts B cells, as a prognostic marker in these patients. A marker measured at the first episode could tell doctors who needs early, strong treatment and who can safely wait. That sorting is one of the most practical problems in MS care.
Catalog record
| CREATOR | Johannes Brettschneider, Anne Czerwoniak, Makbule Senel et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0011986